Terms: = Prostate cancer AND ALDH2, ALDHI, 217, ENSG00000111275, ALDH-E2, P05091, MGC1806, ALDM AND Treatment
80 results:
1. Non-medical interventions to enhance return to work for people with cancer.
de Boer AG; Tamminga SJ; Boschman JS; Hoving JL
Cochrane Database Syst Rev; 2024 Mar; 3(3):CD007569. PubMed ID: 38441440
[TBL] [Abstract] [Full Text] [Related]
2. Comparison of Health-Related Quality of Life Changes in prostate cancer Patients Undergoing Laparoscopic versus Robotic-Assisted Laparoscopic Radical prostatectomy: A Systematic review.
Yazici S; Tonyali S
Urol J; 2024 Feb; 21(1):14-19. PubMed ID: 37727913
[TBL] [Abstract] [Full Text] [Related]
3. The impact of adding cost information to a conversation aid to support shared decision making about low-risk prostate cancer treatment: Results of a stepped-wedge cluster randomised trial.
Politi MC; Forcino RC; Parrish K; Durand MA; O'Malley AJ; Moses R; Cooksey K; Elwyn G
Health Expect; 2023 Oct; 26(5):2023-2039. PubMed ID: 37394739
[TBL] [Abstract] [Full Text] [Related]
4. Salvage Radiation Therapy After Radical prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT Trial.
Petersen PM; Cook AD; Sydes MR; Clarke N; Cross W; Kynaston H; Logue J; Neville P; ; Payne H; Parmar MKB; Parulekar W; Persad R; Saad F; Stirling A; Parker CC; Catton C
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):624-629. PubMed ID: 37150260
[TBL] [Abstract] [Full Text] [Related]
5. FTO-stabilized miR-139-5p targets ZNF217 to suppress prostate cancer cell malignancies by inactivating the PI3K/Akt/mTOR signal pathway.
Azhati B; Reheman A; Dilixiati D; Rexiati M
Arch Biochem Biophys; 2023 Jun; 741():109604. PubMed ID: 37080415
[TBL] [Abstract] [Full Text] [Related]
6. Clinical Validation and treatment Plan Evaluation Based on Autodelineation of the Clinical Target Volume for prostate cancer Radiotherapy.
Shen J; Tao Y; Guan H; Zhen H; He L; Dong T; Wang S; Chen Y; Chen Q; Liu Z; Zhang F
Technol Cancer Res Treat; 2023; 22():15330338231164883. PubMed ID: 36991566
[TBL] [Abstract] [Full Text] [Related]
7. Intensity-modulated radiation therapy for intermediate-risk prostate cancer: does ADT still have an impact in the dose-escalated external beam radiation therapy era?
Soyano T; Kozuka T; Kashihara K; Murakami Y; Yonese J; Sasamura K; Shimoyachi N; Kashihara T; Yoshioka Y; Oguchi M
Jpn J Clin Oncol; 2023 Jun; 53(6):514-521. PubMed ID: 36946312
[TBL] [Abstract] [Full Text] [Related]
8. Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancer.
Lewis AR; Costello BA; Quevedo F; Pagliaro LC; Sanhueza C; Weinshilboum RM; Kalari KR; Wang L; Kohli M; Tan W; Giridhar KV
Prostate; 2023 May; 83(7):649-655. PubMed ID: 36924119
[TBL] [Abstract] [Full Text] [Related]
9. Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive prostate cancer in the LATITUDE Study.
Koroki Y; Taguri M
Target Oncol; 2023 Jan; 18(1):119-128. PubMed ID: 36443540
[TBL] [Abstract] [Full Text] [Related]
10. Predictive value of low testosterone concentrations during and prior to enzalutamide treatment in metastatic castration-resistant prostate cancer.
van Winden LJ; Lanfermeijer M; Dezentje V; Bergman AM; van der Poel HG; van Rossum HH
Urol Oncol; 2023 Feb; 41(2):104.e11-104.e17. PubMed ID: 36379811
[TBL] [Abstract] [Full Text] [Related]
11. Radiation and Chemotherapy are Associated with Altered Aortic Aneurysm Growth in Patients with cancer: Impact of Synchronous cancer and Aortic Aneurysm.
Becker von Rose A; Kobus K; Bohmann B; Lindquist-Lilljequist M; Eilenberg W; Bassermann F; Reeps C; Eckstein HH; Trenner M; Maegdefessel L; Neumayer C; Brostjan C; Roy J; Hultgren R; Schwaiger BJ; Busch A
Eur J Vasc Endovasc Surg; 2022; 64(2-3):255-264. PubMed ID: 35853577
[TBL] [Abstract] [Full Text] [Related]
12. cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study.
Luo Q; O'Connell DL; Yu XQ; Kahn C; Caruana M; Pesola F; Sasieni P; Grogan PB; Aranda S; Cabasag CJ; Soerjomataram I; Steinberg J; Canfell K
Lancet Public Health; 2022 Jun; 7(6):e537-e548. PubMed ID: 35660215
[TBL] [Abstract] [Full Text] [Related]
13. Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual prostate cancer Following Irreversible Electroporation-A Multicenter Validation Study.
Geboers B; Gondoputro W; Thompson JE; Reesink DJ; van Riel LAMJG; Zhang D; Blazevski A; Doan P; Agrawal S; Matthews J; Haynes AM; Liu Z; Delprado W; Shnier R; de Reijke TM; Lawrentschuk N; Stijns PEF; Yaxley JW; Scheltema MJ; Stricker PD
Eur Urol Focus; 2022 Nov; 8(6):1591-1598. PubMed ID: 35577751
[TBL] [Abstract] [Full Text] [Related]
14. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K; Foulon S; Carles J; Roubaud G; McDermott R; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Gravis G; Calabro F; Berdah JF; Hasbini A; Silva M; Thiery-Vuillemin A; Latorzeff I; Mourey L; Laguerre B; Abadie-Lacourtoisie S; Martin E; El Kouri C; Escande A; Rosello A; Magne N; Schlurmann F; Priou F; Chand-Fouche ME; Freixa SV; Jamaluddin M; Rieger I; Bossi A;
Lancet; 2022 Apr; 399(10336):1695-1707. PubMed ID: 35405085
[TBL] [Abstract] [Full Text] [Related]
15. Development and validation of a cell cycle progression signature for decentralized testing of men with prostate cancer.
Kuhl V; Clegg W; Meek S; Lenz L; Flake DD; Ronan T; Kornilov M; Horsch D; Scheer M; Farber D; Zalaznick H; Cussenot O; Compérat E; Cancel-Tassin G; Wild PJ; Chun FK; Mandel P; Moinfar F; Cohen T; Delee S; Kronenwett R; Doedt J
Biomark Med; 2022 Apr; 16(6):449-459. PubMed ID: 35321552
[TBL] [Abstract] [Full Text] [Related]
16. Demographic and Psychosocial Characteristics Associated With Use of a prostate cancer Survivorship Website: Implications From a Multisite Randomized Controlled Trial.
Marziliano A; Diefenbach MA; Hudson SV; Tagai EK; Handorf EA; Bator A; Miller SM
J Med Internet Res; 2022 Mar; 24(3):e27890. PubMed ID: 35311678
[TBL] [Abstract] [Full Text] [Related]
17. [A Case of Pelvic Lymph Node Recurrence Detected by PSMA PET/CT after Primary Proton Beam Radiotherapy for prostate cancer].
Ito T; Yamaguchi Y; Fujimoto N; Watabe T; Ishizuya Y; Uemura M; Nonomura N
Hinyokika Kiyo; 2021 Dec; 67(12):543-546. PubMed ID: 34991296
[TBL] [Abstract] [Full Text] [Related]
18. Proton Beam Therapy for cancer in Children and Adults: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(1):1-142. PubMed ID: 34055109
[TBL] [Abstract] [Full Text] [Related]
19. miR-217-5p Inhibits Invasion and Metastasis of prostate cancer by Targeting Clusterin.
Zhao W; Wang X; Jiang Y; Jia X; Guo Y
Mamm Genome; 2021 Oct; 32(5):371-380. PubMed ID: 33993322
[TBL] [Abstract] [Full Text] [Related]
20. Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: A single-arm phase 3 study.
Zhou T; Zhou F; Guo J; Shi H; Yao X; Guo H; Yuan J; Tian Y; Zhang X; Wang S; Jiang Y; Zou Q; Zhou D; Li H; Li F; Lee JL; Chen CH; Park SH; Ng QS; Ma J; Zheng R; Ding Q; Liu X; Li R; Krissel H; Wagner VJ; Sun Y
Asia Pac J Clin Oncol; 2021 Dec; 17(6):462-470. PubMed ID: 33051982
[TBL] [Abstract] [Full Text] [Related]
[Next]
